There has been significant focus and attention paid to the issue of drug prices in the last few years. As Adam Fein, president of Pembroke Consulting Inc. and chief executive officer of Drug Channels Institute, has said, “Drugs are 12% of the costs, but 90% of the conversation.
Editor’s note: The fourth in a series of seven articles by A.T. Kearney on the trends that are radically transforming the health sector. By Todd Huseby and Carol Cruickshank Traditionally, the approach to health in the United States has been reactive or at best responsive.
The law of the land for almost a decade, the Patient Protection and Affordable Care Act of 2010 is as controversial now as it was when it was enacted.
Editor’s note: This is the third in a series of seven articles by A.T. Kearney on the trends that are radically transforming the health care sector. The promise of consumer-driven health care is not new.
There is a lot of talk in the industry about the role of retail pharmacists and how it will change in response to the aspirations of those professionals; the knowledge and expertise they possess; and the needs of a creaking health care system, notably the problems of patient access and rising expend
Retailers spend millions of dollars combing through data to help them determine ideal store layouts, merchandise packaging and sales strategies to maximize consumer spending over the holiday season. Real-time data tools promise to give organizations a rapid picture of what’s working and what’s not.
The recent partnership of Kroger and Walgreens caught many industry experts off guard largely because the agreement goes against conventional wisdom of maximizing competitive advantages.
Editor’s note: The second in a series of seven articles by A.T. Kearney on the trends that are radically transforming the health sector. There is no question that science is rapidly accelerating the health care opportunities we see in the marketplace.
Despite all the attention that Amazon justifiably receives for the transformational effect it is exerting on mass market retailing, a case can be made that the company that is in the best position to meet the omnichannel needs of consumers over the long term is Walmart.
Pharmacies and grocery stores are better positioned than doctors to promote healthy behavior and prevent debilitating and costly illnesses. Many executives know this, but it is surprising how many acknowledge they have not done much about it.
To address the personal forms of value that tomorrow’s consumers will demand, consumer packaged goods companies need to move from “idle” to “agile.” Chain drug stores are uniquely positioned to help.
For the better part of a decade, Walgreens Boosts Alliance has been engaged in continually rethinking what a chain drug store means to the consumer, and how the format needs to evolve to remain relevant in an era when digital technology is changing the rules of the game in retailing and health care.
On October 27 the Drug Enforcement Agency (DEA) will hold its 14th National Consumer Drug Take-Back Day. The event will be well publicized and will enable the safe and secure disposal of millions of pounds of expired and unneeded prescription medications.
A little over 40 years ago, the first issue of Chain Drug Review appeared.
The appointment of Jim Donald to succeed Bob Miller as chief executive officer of Albertsons Cos. earlier this month symbolizes the company’s ability to maintain its equilibrium when confronted with adversity and find new ways forward.
